Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Reduced by California Public Employees Retirement System

California Public Employees Retirement System lowered its position in Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating) by 19.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,935 shares of the company’s stock after selling 28,766 shares during the quarter. California Public Employees Retirement System’s holdings in Intellia Therapeutics were worth $6,208,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTLA. Prospera Financial Services Inc acquired a new position in shares of Intellia Therapeutics in the 1st quarter worth approximately $32,000. Herold Advisors Inc. bought a new position in Intellia Therapeutics in the 1st quarter valued at $62,000. Penserra Capital Management LLC bought a new position in Intellia Therapeutics in the 1st quarter valued at $97,000. Steward Partners Investment Advisory LLC lifted its stake in shares of Intellia Therapeutics by 10.2% in the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,368 shares of the company’s stock valued at $123,000 after purchasing an additional 220 shares during the period. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Intellia Therapeutics in the 1st quarter valued at $165,000. Hedge funds and other institutional investors own 88.18% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the company. JMP Securities raised their price objective on Intellia Therapeutics from $106.00 to $111.00 and gave the stock a “market outperform” rating in a research note on Monday, September 19th. Chardan Capital raised their price objective on Intellia Therapeutics from $121.00 to $129.00 and gave the company a “buy” rating in a report on Monday, November 14th. Credit Suisse Group raised their price objective on Intellia Therapeutics from $101.00 to $109.00 and gave the company an “outperform” rating in a report on Friday, November 4th. StockNews.com began coverage on Intellia Therapeutics in a report on Wednesday, October 12th. They set a “sell” rating for the company. Finally, Citigroup began coverage on Intellia Therapeutics in a report on Thursday, September 1st. They set a “sell” rating and a $50.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.72.

Intellia Therapeutics Trading Up 2.0 %

Shares of NASDAQ NTLA opened at $49.89 on Friday. The firm’s 50-day moving average price is $53.89 and its 200-day moving average price is $55.07. Intellia Therapeutics, Inc. has a 1-year low of $37.08 and a 1-year high of $130.33. The firm has a market capitalization of $3.93 billion, a P/E ratio of -8.50 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.31) by ($0.18). Intellia Therapeutics had a negative net margin of 859.92% and a negative return on equity of 47.79%. The company had revenue of $13.27 million for the quarter, compared to analyst estimates of $13.60 million. Equities research analysts forecast that Intellia Therapeutics, Inc. will post -6.08 EPS for the current year.

Intellia Therapeutics Company Profile

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Articles

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics, Inc. (NASDAQ:NTLAGet Rating).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.